← Back to Screener
Relmada Therapeutics, Inc. Common Stock (RLMD)
Price$7.37
Favorite Metrics
Price vs S&P 500 (26W)257.96%
Price vs S&P 500 (4W)17.63%
Market Capitalization$773.03M
All Metrics
Book Value / Share (Quarterly)$1.18
P/TBV (Annual)0.62x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.62
Price vs S&P 500 (YTD)48.66%
EPS (TTM)$-1.50
10-Day Avg Trading Volume1.53M
EPS Excl Extra (TTM)$-1.50
EPS (Annual)$-1.45
ROI (Annual)-66.33%
Gross Margin (Annual)0.00%
Cash / Share (Quarterly)$1.27
ROA (Last FY)-61.05%
EBITD / Share (TTM)$-1.50
ROE (5Y Avg)-115.89%
Cash Flow / Share (Annual)$-0.62
P/B Ratio8.94x
P/B Ratio (Quarterly)4.09x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-72.04x
ROA (TTM)-145.58%
EPS Incl Extra (Annual)$-1.45
Current Ratio (Annual)14.62x
Quick Ratio (Quarterly)14.46x
3-Month Avg Trading Volume1.43M
52-Week Price Return2443.13%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.40
P/S Ratio (Annual)77302.63x
52-Week High$7.94
EPS Excl Extra (Annual)$-1.45
26-Week Price Return264.85%
Quick Ratio (Annual)14.46x
13-Week Price Return93.95%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.62x
Enterprise Value$769.53
Book Value / Share Growth (5Y)-28.87%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-500.00%
Cash / Share (Annual)$1.27
3-Month Return Std Dev140.59%
Net Income / Employee (TTM)$-3
ROE (Last FY)-66.33%
Net Interest Coverage (Annual)-48.51x
EPS Basic Excl Extra (Annual)$-1.45
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.50
ROI (TTM)-170.83%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.67
Price vs S&P 500 (52W)2408.50%
Year-to-Date Return52.59%
5-Day Price Return2.50%
EPS Normalized (Annual)$-1.45
ROA (5Y Avg)-99.18%
Net Profit Margin (Annual)-500.00%
Month-to-Date Return5.89%
Cash Flow / Share (TTM)$-3.71
EBITD / Share (Annual)$-1.50
Operating Margin (Annual)-500.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-115.89%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.50
P/TBV (Quarterly)2.00x
P/B Ratio (Annual)4.09x
Book Value / Share (Annual)$1.18
Price vs S&P 500 (13W)91.57%
Beta0.41x
Revenue / Share (TTM)$0.00
ROE (TTM)-170.83%
52-Week Low$0.27
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.33
4.33
4.27
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RLMDRelmada Therapeutics, Inc. Common Stock | — | — | — | — | $7.37 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Relmada Therapeutics is a clinical-stage biotech company developing esmethadone (REL-1017), an oral NMDA receptor antagonist for depression and other central nervous system disorders. The company is focused on addressing high unmet medical needs in CNS disease treatment through novel drug formulations.